Jacob Gottlieb and Stuart Weisbrod are big investors of the healthcare industry, and they have been investing together since Merlin BioMed Group.
Stuart Weisbrod co-founded the Merlin BioMed Group in 1998 as an investment and financial management company specialized in the healthcare industry. The company was focused in the pharmaceutical and biotechnological sectors of the healthcare industry, and Stuart’s group soon became a successful investment management firm of many healthcare professionals.
At Merlin, Weisbrod started to become very successful with his healthcare investments, and he had a lot of experience in the industry, having worked with the Oracle Partners, Harpel partners, and Merrill Lynch, harnessing decades of experience.
Jacob Gottlieb, another expert in the healthcare world, became a part of the Merlin BioMed Group after working as a portfolio manager for Weisbrod in 2000. Jacob, just like Stuart Weisbrod, is an experienced professional in the biotechnology sector, and has contributed to the company with a high percentage of profit.
Jake Gottlieb and Weisbrod worked together for a couple of years before Gottlieb used his experience to inaugurate his own financial management firm: Visium Asset Management. He invested $300 million at the birth of the company, which he quickly recovered with the firm’s profit in a couple of months.
Being the investor and entrepreneur that he is, it wouldn’t take too long for Jake Gottlieb to create another hedge fund management company: Altium Capital.
Altium Capital was founded in 2006, and Oramed Pharmaceuticals Inc, which had a first investment stake of 5.61% of the firm, was influencing the healthcare industry with their technology and advanced treatments. One such example is Oracle’s oral insulin capsule, used in patients that require insulin intake without having to inject it. This technique was the first of its kind, and Oracle holds the title of the first company to discover a method of ingesting insulin in a successful way.
Gottlieb, an investment expert, decided to invest in Oramed because of its potential to change the pharmaceutical industry with its advanced techniques and solutions for the healthcare industry. He is interested in finding new resolutions for typical problems of healthcare.